Cipla — The Respiratory Leader Is Building Its Next Engine

Respiratory is growing. Chronic therapies are expanding. India is scaling. And Cipla is steadily turning its strong domestic franchise into a broader healthcare growth story. Cipla is no longer just a traditional pharma company. It is becoming a diversified healthcare platform with strong brands, chronic therapies and differentiated products. The biggest trigger is India growth. Cipla's One-India business grew 9% in FY26, while its India prescription portfolio crossed ₹9,500 crore. Respiratory, diabetes and cardiac therapies remained key growth drivers.  And respiratory remains the crown jewel. Cipla holds a 26.2% market share in India's respiratory segment, with respiratory growth of 10.9%, while its flagship Foracort crossed the ₹1,000 crore milestone.  Then comes the real opportunity — chronic healthcare. Respiratory ↑ Diabetes ↑ Cardiac ↑ Urology ↑ Consumer Health ↑ Emerging Markets ↑ Cipla is also expanding beyond its established portfolio through partnerships with Eli Lilly, Novartis, Roche and Sanofi, while building exposure to diabetes, obesity, oncology and other high-growth therapies.  And the international business adds another layer. Cipla's FY26 emerging-market and European portfolio generated $780 million, while its US generics business maintained a top-20 position with a 1.57% market share. The company filed 10 products with the US FDA during FY26, including respiratory, peptide and complex-generic opportunities.  This is where the story becomes interesting: Strong brands → Chronic therapies → New launches → Higher mix → Better growth Cipla is also investing heavily in AI, digital capabilities and next-generation drug development — potentially improving productivity across R&D, manufacturing and patient engagement.  Of course, US pricing pressure, regulatory risks, generic competition and product concentration remain important risks. But the structural opportunity is powerful. Respiratory is strong. India is growing.